Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, U.S. Phase II trial in 90 pre-dialysis patients with stage 3 & 4
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury